journal article·2022-01-25

Fibronectin-Coated Metal–Phenolic Networks for Cooperative Tumor Chemo-/Chemodynamic/Immune Therapy via Enhanced Ferroptosis-Mediated Immunogenic Cell Death

Yao Xu, Yunqi Guo, Changchang Zhang, Mengsi Zhan, Liang Jia, Shaoli Song, Chunjuan Jiang, Mingwu Shen, Xiangyang Shi

ACS Nano· Volume 16· Issue 1
Publisher page

Abstract

The development of nanomedicine formulations to overcome the disadvantages of traditional chemotherapeutic drugs and integrate cooperative theranostic modes still remains challenging. Herein, we report the facile construction of a multifunctional theranostic nanoplatform based on doxorubicin (DOX)-loaded tannic acid (TA)–iron (Fe) networks (for short, TAF) coated with fibronectin (FN) for combination tumor chemo-/chemodynamic/immune therapy under the guidance of magnetic resonance (MR) imaging. We show that the DOX-TAF@FN nanocomplexes created through in situ coordination of TA and Fe(III) and physical coating with FN have a mean particle size of 45.0 nm, are stable, and can release both DOX and Fe in a pH-dependent manner. Due to the coexistence of the TAF network and DOX, significant immunogenic cell death can be caused through enhanced ferroptosis of cancer cells via cooperative Fe-based chemodynamic therapy and DOX chemotherapy. Through further treatment with programmed cell death ligand 1 antibody for an immune checkpoint blockade, the tumor treatment efficacy and the associated immune response can be further enhanced. Meanwhile, with FN-mediated targeting, the DOX-TAF@FN platform can specifically target tumor cells with high expression of αvβ3 integrin. Finally, the TAF network also enables the DOX-TAF@FN to have an r1 relaxivity of 6.1 mM–1 s–1 for T1-weighted MR imaging of tumors. The developed DOX-TAF@FN nanocomplexes may represent an updated multifunctional nanosystem with simple compositions for cooperative MR imaging-guided targeted chemo-/chemodynamic/immune therapy of tumors.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Extracellular vesicles in disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, Shanghai Engineering Research Center of Nano-Biomaterials and Regenerative Medicine, College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai 201620, PR China

Department of Nuclear Medicine, Shanghai Cancer Center, Fudan University, Shanghai 200030, PR China

Funding

Ministry of Education of the People's Republic of China · Science and Technology Commission of Shanghai Municipality · National Natural Science Foundation of China · Shanghai Education Commission through the Shanghai Leading Talents Program · Sino-German Center for Research Promotion

References (46)

Show source-provided references
1. 10.1021/acsnano.0c0688110.1021/acsnano.0c06881 ↗
2. 10.3390/molecules2606179210.3390/molecules26061792 ↗
3. 10.2967/jnumed.107.03985910.2967/jnumed.107.039859 ↗
4. 10.1021/acsami.8b1930410.1021/acsami.8b19304 ↗
5. 10.1021/acsnano.8b0978610.1021/acsnano.8b09786 ↗
6. 10.1002/smll.20160258010.1002/smll.201602580 ↗
7. 10.1016/j.biomaterials.2019.03.02010.1016/j.biomaterials.2019.03.020 ↗
8. 10.1021/acs.chemmater.9b0304210.1021/acs.chemmater.9b03042 ↗
9. 10.1016/j.ejpb.2021.05.01210.1016/j.ejpb.2021.05.012 ↗
10. 10.1021/acs.nanolett.9b0414710.1021/acs.nanolett.9b04147 ↗
11. 10.1016/j.nantod.2020.10094610.1016/j.nantod.2020.100946 ↗
12. 10.1002/adma.20190419710.1002/adma.201904197 ↗
13. 10.1021/acsnano.8b0560210.1021/acsnano.8b05602 ↗
14. 10.1002/anie.20180566410.1002/anie.201805664 ↗
15. 10.1111/jcmm.1300810.1111/jcmm.13008 ↗
16. 10.1039/D0TB00008F10.1039/D0TB00008F ↗
17. 10.1021/acs.nanolett.8b0317810.1021/acs.nanolett.8b03178 ↗
18. 10.1016/j.jconrel.2020.09.00910.1016/j.jconrel.2020.09.009 ↗
19. 10.1007/s00604-021-04810-410.1007/s00604-021-04810-4 ↗
20. 10.1021/acsami.8b0461310.1021/acsami.8b04613 ↗
21. 10.1021/acsnano.6b0469510.1021/acsnano.6b04695 ↗
22. 10.1016/j.nantod.2020.10102210.1016/j.nantod.2020.101022 ↗
23. 10.1016/j.bioactmat.2021.02.02110.1016/j.bioactmat.2021.02.021 ↗
24. 10.1002/smll.20200021410.1002/smll.202000214 ↗
25. 10.1002/adma.20190491410.1002/adma.201904914 ↗
26. 10.1016/j.ajps.2020.05.00410.1016/j.ajps.2020.05.004 ↗
27. 10.3389/fimmu.2015.0027510.3389/fimmu.2015.00275 ↗
28. 10.1038/nrc338010.1038/nrc3380 ↗
29. 10.1002/adfm.20190974510.1002/adfm.201909745 ↗
30. 10.2147/IJN.S28599910.2147/IJN.S285999 ↗
31. 10.1016/j.biomaterials.2016.06.03210.1016/j.biomaterials.2016.06.032 ↗
32. 10.3390/cancers1307163910.3390/cancers13071639 ↗
33. 10.3389/fcell.2021.70719810.3389/fcell.2021.707198 ↗
34. 10.3389/fonc.2020.58436710.3389/fonc.2020.584367 ↗
35. 10.1158/2159-8290.CD-18-125910.1158/2159-8290.CD-18-1259 ↗
36. 10.1016/j.cdtm.2019.08.00310.1016/j.cdtm.2019.08.003 ↗
37. 10.1016/j.lfs.2021.11981310.1016/j.lfs.2021.119813 ↗
38. 10.1039/D1NR03288G10.1039/D1NR03288G ↗
39. 10.1002/smll.20200170410.1002/smll.202001704 ↗
40. 10.1016/j.bbrc.2016.03.05210.1016/j.bbrc.2016.03.052 ↗
41. 10.1016/j.carbpol.2021.11821110.1016/j.carbpol.2021.118211 ↗
42. 10.1002/advs.20210016510.1002/advs.202100165 ↗
43. 10.1002/admi.20150025610.1002/admi.201500256 ↗
44. 10.1039/C7QM00570A10.1039/C7QM00570A ↗
45. 10.1002/adfm.20190244010.1002/adfm.201902440 ↗
46. 10.1002/adma.20180500710.1002/adma.201805007 ↗